• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a composition for targeting an anticancer agent, comprising an iodinated oil and a surfactant of formula (I): embedded image in which: s is 0 or 1, m represents an integer of 2 to 30, R 1 represents a grouping; of formula (II) wherein n is an integer of 4 to 10, o is an integer of 1 to 4, p is an integer of 3 to 7, q is an integer of 2 to 10 and r is 0 or 1, - R2 represents a hydrogen atom or is identical to R1. It also relates to an emulsion obtained from this composition, its method of preparation and its use in the treatment of cancer and its metastases.
    公开号:FR3017295A1
    申请号:FR1450972
    申请日:2014-02-07
    公开日:2015-08-14
    发明作者:Caroline Robic；Jean-Francois Mayer
    申请人:Guerbet SA；
    IPC主号:
    专利说明:

    [0001] The present invention relates to a composition for targeting an anticancer agent, comprising an iodized oil and a surfactant useful for the preparation of a composition in the form of a water-in-oil emulsion comprising an anti-cancer agent, an iodized oil and this surfactant. For over a century, iodized oils such as Lipiodol® have been used as a contrast medium in radiological examinations such as lymphography and for the diagnosis of liver damage. Lipiodol® is mainly composed of ethyl esters of iodized fatty acids from the oil of the tree. For nearly thirty years, these iodized oils have been used in interventional radiology procedures. Lipiodol® is characterized by its propensity to be picked up selectively by liver tumors. It has therefore been proposed as an anticancer agent for the treatment of hepatocellular carcinoma in a technique called intraarterial chemoembolization or "TransArterial ChemoEmbolisation" (TACE) in English (Nakamura et al .: Radiology, 1989; : 783-6 and JM Idea - B. Guiu: Critical Reviews in Oncology / Hematology, 2013; 88 (3): 530-49). Iodized oils and in particular Lipiodol® are also known to induce a transient embolization of the arterial circulation thus causing a slowdown of it. Since most anticancer agents are soluble in water, the "emulsion" form, which is suitable for mixing two insoluble phases together, appears to be the most suitable for mixing an oil. iodine and an anticancer agent. It seems to be the most suitable for transporting and delivering into a tumor an anti-cancer agent, which is too toxic and not sufficiently effective when it is administered non-emulsified by the intra-arterial route or systemically.
    [0002] An emulsion "water-in-oil" emulsion called "inverse" is an emulsion that is noted E / H in French or W / O (water in oil) in English. It is a dispersion of droplets of aqueous phase in a lipid phase. An "oil-in-water" emulsion is a so-called "direct" emulsion that is noted as H / E in French or 0 / W (oil in water) in English. In contrast to W / O emulsions, it is then a dispersion of lipid phase droplets in an aqueous phase. The term "emulsion direction" is used when referring to the W / O or O / W nature of an emulsion.
    [0003] Oil-in-water (O / W) emulsions, which comprise the anti-cancer agent in the aqueous continuous phase, have the important disadvantage of rapidly releasing the anticancer agent into the blood. A significant part of the therapeutic agent does not reach the targeted site, which can, on the one hand, induce systemic toxicity and on the other hand reduce the effectiveness of this therapeutic agent. In addition, this type of O / W emulsion has the risk of causing pulmonary or even cerebral embolism. This risk is increased when the size of the oil droplets of these emulsions is less than 10 μm. This second disadvantage is difficult to discard since by increasing the size of the droplets, the instability of these emulsions is increased. Water-in-oil emulsions (W / O or W / O), also known as "inverse emulsions", and comprising an iodized oil and an anticancer agent, are less mentioned in the literature than O / W emulsions. They are described as more slowly releasing the therapeutic agent into the tumor and having a higher viscosity than oil-in-water emulsions (De Baere et al., Radiology 1995; 194: 165-170). These reasons encourage choosing a form of W / O emulsion to vector an anticancer agent within a tumor. However, these W / O emulsions do not always have sufficient efficacy because of their lack of stability in contact with blood and vascular bifurcations upstream of the tumor. Indeed, to increase the tumor targeting of anticancer agents and at the same time improve the therapeutic efficacy and the tolerance of the treatment, an emulsion must remain stable until it reaches the tumor and its distribution in the tumor lesion must be complete. and homogeneous.
    [0004] Various solutions for stabilizing emulsions have thus been proposed in the prior art. To stabilize O / W emulsions, many authors have proposed the use of surfactant with high HLB (more than 8).
    [0005] The use of high or very high HLB surfactants such as polyoxyethylenated fatty acid and sorbitan esters, polyoxyethylenated sorbitan monostearate or polysorbate 60 (Montanox® 60, HLB = 14.9) and polyoxyethylenated sorbitan monolaurate or polysorbate (Montanox 20®, HLB = 16.7) has been described for the preparation of stable 6-month-old idarubicin and Lipiodol®-based oil-in-water emulsions. JPH0647559 discloses an O / W emulsion comprising between 10 and 30% of Lipiodol®, an anticancer agent and between 0.1 and 2% of a hydrophilic surfactant, HCO-60 otherwise known as polyoxyethylene hydrogenated castor oil (HLB = 14). It is a priori a PEG-60 linked to a ricinoleic acid.
    [0006] EP 0 294 534 describes an emulsion contrast medium made from an emulsified iodinated oil using organic compounds such as amino acids (phenylalanine, alanine, leucine, isoleucine, glycine, serine or taurine), fatty acids such as pelargonic acid, oleic acid (HLB = 17) or linoleic acid (HLB = 16) or a fat-soluble vitamin such as vitamin E. EP 0 581 842 discloses an oil-in-water emulsion comprising iodinated fatty acid esters derived from emulsified poppy seed oil with the aid of a mixture of phospholipids and cyclopentaphenanthrene derivatives such as sterols.
    [0007] EP 0 294 534 and EP 0 581 842 refer to other documents. In particular, DE 26 02 907 describes an oil-in-water emulsion containing between 50 and 60% of iodinated triglycerides, between 2 and 10% of polyoxyethylene sorbitan fatty acid esters (HLB = 13 to 17) and between 2 and 40% water. Grimes et al. (J.
    [0008] Pharm. Sci. 1979 Jan; 68 (1): 52-6) discloses the use of polysorbate 80 (HLB = 15), sorbitan mono-oleate (HLB = 8.6) and phosphatidylcholine to obtain emulsions comprising iodinated oil . Vermess et al. described emulsions (US 4,404,182 or J. Comput Assist Tomogr 3: 25-31, 1979) containing 53% (v / v) Lipiodol®, 10% alcohol and 0.45% soy lecithin. . These oil-in-water emulsions have particle sizes of 2 to 3 Schumacher et al. (Europ.J. Radiol.5, 167-174, 1985) describes different emulsions containing iodinated oils and prepared using emulsifiers such as polyoxyethylene-4-sorbitan monolaurate (Tween® 80, Serva: HLB = 15, 3), glycerol polyethylene glycol ricinoleate (Cremophor® EL: HLB = 14.5), diacetylphosphate DP (Sigma), lecithin from eggs (Fluka GmbH), Doxypolygelatin (Gelinfundol® 5.5% Biotest GmbH) and dextran 60 ( Macrodex® 4.5%, RL Knoll). GB 676,738 discloses emulsions containing iodinated oils and synthetic nonionic emulsifiers such as monoesters of fatty acids and of polyhydroxyalcohols (sorbitol monoesters of lauric acid, palmitic acid, stearic acid or oleic acid, mono-esters of glycerol and fatty acids such as glycerol mono-stearate and glycerol mono-oleate, mono-glycol esters such as ethylene glycol, tetra-ethylene glycol or dodecaethylene glycol with fatty acids such as palmitic acid, stearic acid or lauric acid), these esters being able to react with polyalkylene oxides to form polyoxyalkylene derivatives. No. 3,356,575 describes an emulsion containing an iodized oil, glycerol and lecithin. No. 4,917,880 describes an emulsion comprising 10% iodinated oil and in the aqueous phase, 1.2% purified phospholipids of eggs with 2.25% glycerol and 0.1% phenylalanine. The use of amiodarone (an antiarrhythmic drug of the chemical formula 2-butyl-3-benzofuranyl) [412- (diethylamino) ethoxy] -3,5-diiodophenyl] methanone stabilized an oil-in-water emulsion of Lipiodol. ® (44% (v / v)) and doxorubicin or pirarubicin up to four weeks at 37 ° C. This property is due to the presence of an excipient in this drug, polysorbate 80, a high HLB emulsifier (Boulin et al., Digestive and Liver Disease 43 (2011) 905-911). Further work by the same team has shown that amiodarone does not improve the stability of an emulsion based on Lipiodol® and idarubicin and does not appear to increase the cytotoxicity of the anticancer agent. The use of idarubicin and Lipiodol® alone is therefore recommended. In Nakamura et al. (Radiology, 1989; 170: 783-6) is shown the visual appearance of different emulsions obtained by mixing 1 ml of distilled water comprising an ionic contrast product, sodium diatrizoate and meglumine (Hypaque®, Gastrografin® or Urografin®) and 3 mL of Lipiodol® (Figure 1). It is indicated that the emulsion C has not shifted after 24 hours but it can easily be seen in this figure that this emulsion is actually not stable, the lower part of the tube which contains it, being more clear than the part superior of it. In this document is also described the emulsion preparation of Lipiodol® and doxorubicin or mitomycin in ratio 2-3 / 1. It is indicated that the emulsion obtained is an W / O emulsion. It is emphasized the less release of the anti-cancer agent in the case of the use of this emulsion (Figure 2). The plasma peak visualized after injection of this emulsion remains nonetheless significant. This emulsion must not be sufficiently stable since there is no use of surfactant. Indeed, 2 minutes after intra-arterial injection of their emulsion, a lower plasma concentration of doxorubicin of 83% ((((3500-600) / 3500) is observed compared to the plasma concentration measured after injection of this anticancer agent alone. At 5 minutes, this decrease is 80%.
    [0009] In Raoul et al. (Cancer, 1992, vol.70, No. 3, 585-90) are described emulsions comprising 50 mg of doxorubicin made by mixing 10 mL of Lipiodol® and 2.5 mL of ioxaglate (Hexabrix®). The emulsions obtained, whose direction W / H or O / W is not specified, cause a plasma peak significantly lower than that caused by the intra-arterial injection of doxorubicin alone. However, this peak plasma indicates a significant passage of the anticancer agent in the blood. Indeed, 2 minutes after intra-arterial injection of these emulsions, a lower plasma concentration of doxorubicin of 59% (((2200-900) / 2200) is observed compared to the plasma concentration measured after injection of this anticancer agent alone. The calculation corresponding to 5 minutes after injection is even more unfavorable since this reduction is then only 33% (((1050 - 700) / 1050) x 100).
    [0010] When an embolization is performed after injection of these emulsions, these decreases are at 2 and 5 minutes respectively of 82% (((2200 - 400) / 2200) x 100) and 43% (((700-400) / 700) x 100). These different emulsions, when they are in "oil-in-water" form, have a capacity to vector anti-cancer agents that are insufficient, even if they have been stabilized with high HLB surfactant and their use always presents a risk. important of embolism. This insufficient vectorization capacity is explained by the nature of the emulsion since in the case of oil-in-water emulsions, the anti-cancer agent, most often water-soluble, is in the aqueous continuous phase and is therefore very rapidly diluted in the bloodstream. In addition, several of these emulsions contain synthetic emulsifiers such as Tween® (high HLB) or Span® (HLB either low or high), emulsifiers listed in the European Pharmacopoeia, which cause side effects. Polysorbates such as Tweenes are described as potentially toxic. Sorbitan esters such as Spann are not recommended for use in parenteral injection. (Handbook of Pharmaceutical Excipients, 2009). Frequently, emulsions described in publications such as "water-in-oil" emulsions are not emulsions of this nature. When actually in the W / O form, these emulsions have insufficient stabilities and anti-cancer agent delivery capabilities. They therefore have an insufficient efficacy after injection since a large part of the quantity of anti-cancer agent injected intraarterially does not reach the level of the targeted lesion (Raoul et al., 1992). at the point a composition for producing a water-in-oil emulsion comprising a stable anti-cancer agent for at least 24h at 20 ° C and generally having an improved vectorization capacity compared to the emulsions of the prior art. This emulsion has two major advantages: it is easily used in a hospital context, its stability allowing it to be prepared at least 24 hours in advance in the hospital pharmacy and it presents a very limited risk for the patient, while having improved therapeutic efficacy. Thus, the subject of the invention is a composition comprising an iodinated oil and at least one surfactant of formula (I): ## STR2 ## in which: s is 0 or 1, m represents a number integer from 2 to 30, R1 represents a group of formula (II) wherein n represents an integer from 4 to 10, o represents an integer from 1 to 4, p represents an integer from 3 to 7, q represents an integer from 2 to 10 and r is 0 or 1, R2 represents a hydrogen atom or is identical to R1. This composition is intended to vector an anticancer agent. The invention also relates to the use of this composition as a carrier of an anticancer agent. This composition can be in the form of a water-in-oil emulsion (also called "stable inverse emulsion" or W / O or W / O). Such an emulsion consists of a lipid phase and an aqueous phase dispersed in the form of droplets. The iodinated oil of the composition is in the lipid phase. The surfactant of formula (I) is located at the interface between the aqueous and lipid phases. For the purposes of the present application, for the calculation of proportions of aqueous and lipid phases, it will be considered that the surfactant is in the lipid phase. Preferably, the aqueous phase of the emulsion comprises an anticancer agent. Typically, the composition is in the form of a water-in-oil emulsion which comprises: - an aqueous phase, in the form of droplets, comprising an anti-cancer agent, and a lipid phase comprising an iodized oil and at least one surfactant of formula (I) as defined above. Preferably, the composition according to the invention is a water-in-oil emulsion which comprises: from 20 to 40% (v / v), preferably from 20 to 35%, more preferably 25% of aqueous phase, in the form of droplets, comprising an anticancer agent, and from 60 to 80% (v / v), preferably from 65 to 80% (v / v), more preferably 75% (v / v) of lipid phase comprising an iodized oil and at least one surfactant of formula (I) as defined above in a proportion, by weight of surfactant relative to the total volume of the composition, of 0.3 to 5%, preferably of 0.5 to 2%, more preferably 1%. The proportion of surfactant is expressed as a weight of surfactant over the total volume of the composition in emulsion form. The proportions in the aqueous or lipid phases are expressed as the volume of the phase on the total volume of the composition in emulsion form. In particular, the following embodiments are advantageous: (3/0 (v / v)% (v / v)% (w / v) of at least one lipid phase aqueous phase surfactant comprising an iodinated Droplet form comprising an anti-cancer agent Composition in the form of an emulsion according to the invention The emulsion is advantageously stable. "Stable" means an emulsion having, under standard conditions of temperature (20 ° C.) and atmospheric pressure (1 bar) and within 24 hours after its preparation, a visual phase shift of less than 5% by volume relative to to the totality of the composition in emulsion form Preferably, by "stable" emulsion is meant an emulsion having no visual phase shift in the conditions mentioned above and within 24 hours of its preparation. when u no solution no longer appears homogeneous, that is to say at the moment when we see the appearance of at least two phases. More preferably, the term "stable" emulsion means an emulsion whose average droplet size varies by less than 10%, in particular by less than 5%, preferably of which the average size of the droplets does not vary, where the size medium is measured under an optical microscope (eg the LEICA DM2000 LED microscope) 24 hours after its preparation. Preferably, the intra-arterial injection of the emulsion according to the invention induces a decrease in the plasma concentration of the anticancer agent between 0 and 5 minutes following this injection of more than 90%, preferably more than 94%, more preferably more than 97%, even more preferably more than 99% relative to the intra-arterial injection of the anticancer agent alone. Advantageously, these plasma concentrations and this decrease are confirmed by plasma kinetic measurements according to protocols known to those skilled in the art.
    [0011] The expression of the difference between a peak plasma concentration of an anti-cancer agent after injection of a particular product comprising this agent and that obtained after injection of the anticancer agent alone is notably mentioned by Hong et al. (Clin Cancer Res 2006: 12 (8)).
    [0012] When the emulsion comprises less than 20% (v / v) of aqueous phase, the anti-cancer agent is difficult to solubilize therein. When the emulsion comprises more than 40% of aqueous phase, the viscosity of the composition in emulsion form is too high. In fact, by increasing the droplet concentration of the aqueous phase in the continuous lipid phase comprising an iodinated oil, the viscosity of the overall composition is increased. The aqueous phase comprises an anti-cancer agent at a therapeutically effective dose. The term "therapeutically acceptable dose" is intended to mean a dose that makes it possible to treat a cancer or to slow down its progression.
    [0013] The density of the lipid phase is preferably from 1.10 to 1.30, more preferably from 1.20 to 1.30, more preferably from 1.28. Preferably, the aqueous phase and the lipid phase have the same density (in other words, they are of equal density) or densities up to 5% different from each other. In order to increase the density of the aqueous phase, a densifying agent may be added thereto (a densification of this phase comprising an anticancer agent) is then carried out. In contrast, in order to reduce the density of the lipid phase comprising an iodized oil, a second oil with a density of less than 1 may be added (a "de-densification" of the lipid phase comprising an iodized oil is then performed). In an advantageous embodiment, the aqueous phase may thus further comprise a densifying agent, preferably at least one nonionic iodinated contrast product. The nonionic iodine product, which can be used as a densifying agent, is preferably chosen from iobitridol (Xenetix®), iopamidol (lopamiron®, Isovuee), iomeprol (lomeron®), ioversol (Optiray®, Optiject®), iohexol (Omnipaque®), iopentol (Imagopaquee), ioxitol (Oxilan®), iopromide (Ultravist®), metrizamide (Amipaque®), iosarcol (Melitrast®), iotrolan (lsoviste), iodixanol (Visipaque®), iosimenol and iosimide (Univist®) and a mixture thereof. Iobitridol is the preferred nonionic iodine product. Xenetix® 250 and Xenetix® 300 products have densities of 1.28 and 1.34, respectively. These nonionic iodinated contrast products have the advantage of allowing good solubility of the anticancer agent in the aqueous phase and of not destabilizing the emulsion.
    [0014] The use of ionic iodinated contrast media such as ioxaglic acid (Hexabrix®) or meglumine and / or sodium diatrizoate (Hypaque®, Gastrografin®, Gastroview® or Urografin®) is not indicated as these Contrast has the disadvantage of reducing the solubility of the anticancer agent in the aqueous phase, or even preventing their solubilization and / or increasing the osmolality of the compositions.
    [0015] In another advantageous embodiment (which may or may not be combined with the above embodiment in which the aqueous phase comprises a densifying agent), the lipid phase may also comprise at least one non-iodized oil with a density of less than 1, preferably a non-iodinated oil with a density of less than 0.96, and even more preferably a non-iodinated oil chosen from linseed oil, soybean oil, palm oil, coconut oil, castor oil, corn oil, cottonseed oil, peanut oil, sesame oil, sunflower oil, safflower oil, almond oil, olive oil, poppy oil and an oil comprising or consisting of a mixture of fatty acid triglycerides of formula: ## STR1 ## wherein R is an aliphatic chain comprising 3 to 35 carbon atoms, provided that more than 95% of said fatty acids are C8 and / or 010, sold for example under the name MIGLYOL®, for example, MIGLYOL® 810 oil, MIGLYOL® 812 0 (caprylic / capric triglyceride) oil, MIGLYOL® 818 (caprylic / capric / linoleic triglyceride) oil, MIGLYOL® 612 (glyceryl trihexanoate) oil or other derivatives MIGLYOL® propylene glycol dicaprylate dicaprate. The expression (R = C8 + O10)> 95% means that the triglycerides of the mixture are fatty acid triglycerides of which more than 95% are C8 and / or 010 fatty acids (capric or caprylic acid). When the fatty acid is C8, R is a chain comprising 7 carbon atoms and when the fatty acid is C10, R is a chain comprising 9 carbon atoms. The densities of the various non-iodinated oils listed are given in the following table: Name of the oil Density Linseed oil 0.94 Soybean oil 0.92 Miglyol® oil 0.94 Palm oil 0.90 Coconut oil 0 , 92 Castor oil 0,96 Corn oil 0,90 Cottonseed oil 0,92 Peanut oil 0,92 Sesame oil 0,92 Sunflower oil 0,93 Safflower oil 0,92 Almond oil 0 , 91 Olive oil 0.915 Poppy seed 0.928 In this specific embodiment, the density of the lipid phase comprising the iodized oil and one or more non-iodinated oils as defined above is then preferably from 0.9 to 1.2, more preferably from 0.95 to 1.10, still more preferably from 1.05. The size of the aqueous phase droplets is preferably from 1 to 200, more preferably from 5 to 100 .mu.m, more preferably from 5 to 50 .mu.m. This size further improves the stability of the emulsion. The size can be measured under an optical microscope (for example the LEICA DM2000 LED microscope).
    [0016] Preferably, the droplets of aqueous phase are distributed homogeneously. The homogeneity is checked using an optical microscope: if aggregates of droplets are observed, these droplets are not distributed homogeneously.
    [0017] The aqueous phase / lipid phase volume ratio in the emulsion composition according to the invention is advantageously from 1/2 (ie 0.5) to 1/4 (ie 0.25), preferably from 2: 5. (ie 0.4) to 3/10 (0.3), more preferably 1/3 (or about 0.33). A ratio of less than 1/2 makes it possible to obtain a W / O emulsion. Indeed, a 1/1 ratio between the lipid phase and the aqueous phase naturally favors an O / S direction. To force the W / O direction, the amount of iodinated oil added must be increased. Beyond a 1/4 ratio, the risk of embolism becomes important. Indeed, so as to solubilize a therapeutically effective amount of anticancer agent in the aqueous phase, it is necessary that this aqueous phase has a sufficient volume. Having a lipid phase comprising an iodized oil and being more than 4 times larger than the aqueous phase, generally has the consequence that the dose of iodized oil used becomes greater than the authorized limit. In the legal notice concerning a product like Lipiodol®, it is indicated that the volume injected into an interventional radiology procedure must not exceed 15 mL.
    [0018] The aqueous and lipid phase volume percentages and the aqueous phase / lipid phase volume ratio of the emulsion composition according to the invention make it possible systematically to obtain an inverse emulsion (W / O) which makes it possible to improve the delivery. an anticancer agent into a tumor.
    [0019] Advantageously, the composition according to the invention has a viscosity at 20 ° C ranging from 100 to 200 mPa.s, preferably from 120 to 170 mPa.s, more preferably from 150 to 165 mPa.s, and / or a viscosity at 37 ° C of 40 to 80 mPa.s, preferably of 50 to 70 mPa.s, more preferably of 60 to 70 mPa.s. The viscosity values are obtained using a Malvern Instruments Kinexus Pro rheometer, having a 4 ° cone-plane cell with a diameter of 40 mm. The measurements are carried out at imposed stress in a range from 0.16 to 10 Pa. Iodinated oils The term "fatty acid" refers to saturated or unsaturated aliphatic carboxylic acids having a carbon chain of at least 4 carbon atoms. . Natural fatty acids have a carbon chain of 4 to 28 carbon atoms (usually an even number). It is called a "long chain fatty acid" for a length of 14 to 22 carbons and a very long chain if there are more than 22 carbons. On the contrary, it is called "short chain fatty acid" for a length of 4 to 10 carbons, especially 6 to 10 carbon atoms, in particular 8 or 10 carbon atoms. The person skilled in the art knows the associated nomenclature and in particular uses: Ci-Cp to designate a range of C1-Cp-Ci + Cp fatty acids, the total of C1 fatty acids and Cp fatty acids For example: the fatty acids of 14 to 18 carbon atoms are written as "C14-C18 fatty acids", the total of the C16 fatty acids and C18 fatty acids is written as C16 + C18. for a saturated fatty acid, a person skilled in the art will use the following nomenclature Ci: 0, where i is the number of carbon atoms of the fatty acid. Palmitic acid will for example be designated by the nomenclature (C16: 0). for an unsaturated fatty acid, one skilled in the art will use the following nomenclature Ci: x nN where N will be the position of the double bond in the unsaturated fatty acid starting from the carbon opposite the acid group, i is the number of atoms of carbon of the fatty acid, x is the number of double bonds (unsaturations) of this fatty acid. The oleic acid, for example, will be designated by the nomenclature (C18: 1 n-9). Advantageously, the iodinated oil according to the invention comprises or consists of iodinated fatty acid derivatives, preferably ethyl esters of iodinated fatty acids, more preferably ethyl esters of iodized fatty acids of iodinated fatty acids. vinegar, olive oil, rapeseed oil, peanut oil, soybean oil or nut oil, even more preferably ethyl esters of fatty acids iodized with olive oil or olive oil. More preferably, the iodinated oil according to the invention comprises or consists of ethyl esters of iodized fatty acids of vinegar oil (also called black poppy or Papaver somniferum var nigrum). The vine oil, also called poppy seed oil or vine seed oil, preferably contains more than 80% of unsaturated fatty acids (in particular linoleic acid (C18: 2 n-6) and oleic acid (C18: 1 n-9)) of which at least 70% linoleic acid and at least 10% oleic acid. The iodinated oil is obtained from the complete iodination of an oil such as cinnamon oil under conditions permitting binding of an iodine atom for each double bond of the unsaturated fatty acids (Wolff et al. 2001, Medicine 80, 20-36) followed by trans-esterification. The iodinated oil according to the invention preferably contains 29 to 53% (w / w), more preferably 37% to 39% (w / w) of iodine. Examples of iodinated oils that may be mentioned are Lipiodol®, Brassiodol® (derived from rapeseed oil (Brassica compestis), Yodiol® (derived from peanut oil), Oriodol® ( from olive oil but in the form of triglycerides of fatty acids), Duroliopaque® (derived from olive oil) Preferably, the iodized oil is Lipiodol®, an iodinated oil used as a product. In some interventional radiology procedures, this oil is a mixture of ethyl esters of iodized and non-iodinated fatty acids of vine seed oil, and consists mainly of (more than 84%) a mixture of ethyl esters of long-chain iodinated fatty acids (in particular C18 fatty acids) derived from the vine seed oil, preferably in a mixture of ethyl monoiodostearate and ethyl diiodostearate The iodized oil can also be an oil based on ethyl ester monoio stearic acid dice (C18: 0) from olive oil.
    [0020] A product of this type, called Duroliopaque®, was marketed a few years ago. The main characteristics of Lipiodol® are the following: Compounds Proportions in the fatty acid mixture ethyl palmitate (Ethyl C16: 0) 4.6 to 6.7% (m / m), preferentially 4.8% (m / m) ethyl stearate (Ethyl C18: 0) 0.8 to 1.9% (w / w), preferably 1.2% (w / w) ethyl monoiodostearate 11.3 to 15.3% ( m / m), preferably 13.4% (m / m) Ethyl diiodostearate 73.5 to 82.8% (w / w), preferably 78.5% (w / w) Other Lipiodole characteristics: Iodine 37% to 39% (m / m) (ie 480 mg / ml) Viscosity at 37 ° C at 20 ° C 25 mPa.s 50 mPa.s Density 1,268 - 1,290 g / cm3 at 20 ° C, preferentially 1,28 Preferably, the amount of iodinated oil present in the composition according to the invention does not exceed 15 ml.
    [0021] Anti-cancer agent The anti-cancer agent vectorized by the composition according to the invention or included in the composition in emulsion form according to the invention is preferably chosen from anthracyclines, platinum complexes, anthracycline-related compounds such as mitoxantrone and nemorubicin, antibiotics such as mitomycin C (Ametycine®) and bleomycin, other anti-neoplastic compounds such as irinotecan, 5-Fluoro-Uracil (Adrucil®), sorafenib (Nevaxar®), regorafenib , brivanib, orantinib, linsitinib, erlotinib, fotemustine, cytosine C, cyclophosphonamide, cytosine arabinoside (or cytarabine), paclitaxel, methotrexate, everolimus (Afinitor®), PEG- arginine deiminase, the combination tegafur / gimeracil / oteracil (Teysuno®), muparfostat, peretinoine, gemcitabine, bevacizumab (Avastin®), ramucirumab, radioelements, complexes of these radioelements a with chelates, iron-based magnetic particles ("ultrasmall superparamagnetic particles of iron oxide" or USPI0s), radioactive microspheres, nucleic acid sequences and a mixture of one or more of these compounds ( preferably a mixture of one or more anthracyclines or a mixture of an anthracycline and a radioelement as mentioned above or a mixture of an anthracycline and a particle based on an iron compound).
    [0022] The emulsion composition may comprise one or more anticancer agents. Preferably, at least one anti-cancer agent is water-soluble, i.e., it is more than 50% soluble in the aqueous phase. Also, when the composition in emulsion form comprises only an anti-cancer agent, it is preferably water-soluble and is therefore in the dispersed aqueous phase. When the emulsion composition comprises several anti-cancer agents, some of them may be in the continuous lipid phase. The preferred anti-cancer agent is selected from anthracyclines, mitomycin C, platinum complexes, radioelements and complexes thereof listed above. The anticancer agent is more preferably chosen from anthracyclines and even more preferentially from doxorubicin, epirubicin, nemorubicin and idarubicin.
    [0023] Advantageously, the anti-cancer agent is chosen from intercalating agents such as doxorubin, epirubicin, idarubicin, nemorubicin, mitoxantrone and pirarubicin; alkylating agents such as cisplatin, carboplatin, oxaliplatin, lobaplatin, cyclophosphonamide and mitomycin C, fotemustine; type 1 topoisomerase inhibitors such as irinotecan; topoisomerase type 2 inhibitors such as doxorubicin and mitoxantrone; tyrosine kinase inhibitors such as everolimus; multikinase inhibitors such as sorafenib; antimetabolites such as 5-fluoro-uracil, methotrexate and gemcitabine, radioelements as listed above, complexes of these radioelements with macrocyclic chelates, magnetic particles based on an iron compound, radioactive microspheres, nucleic acid sequences and a mixture thereof. Preferably, the anthracyclines mentioned above are chosen from doxorubicin (or adriamycin sold under the name Adriblastine® by Pfizer), epirubicin (Farmorubicine®), idarubicin (Zavedos®), daunorubicin, pirarubicin, nemorubicin and mixing one or more of these compounds. Preferentially, the platinum complexes mentioned above are chosen from cisplatin (Platinol AQ®), carboplatin, miriplatin, oxaliplatin, lobaplatin and the mixture of one or more of these compounds.
    [0024] Preferably, the radioelements mentioned above are selected from Rhenium 186 (186Re), Rhenium 188 (188Re), Yttrium 90 (30Y), Lutetium 177 (177Lu), Holmium 166 (166Ho), Iodine 125 (1251), Iodine 131 (1311), Phosphorus 32 (32P), Strontium 89 (89Sr), Samarium 153 (1535m), Copper 67 (67Cu), Tin 117m (117mSn) ), Bismuth 213 (213Bi), Bismuth 212 (212Bi), Astate 211 (211At), Radium 223 (223Ra) and a mixture of one or more of these compounds. The radioelement, optionally in complexed form with linear or macrocyclic chelates, is more preferentially chosen from among 188Re, 90Y, "Lu, 166H0, and 131I. Preferably, the chelates of the complexes of these radioelements mentioned above are chosen from linear chelates and macrocyclic chelates such as DOTA, PCTA, DTPA, NOTE and their derivatives, more preferably among macrocyclic chelates such as DOTA, PCTA, NOTE and their derivatives Yttrium 90 (90Y) and the complexes of Yttrium 90 and macrocyclic chelates as defined above are preferred compounds in their respective classes.
    [0025] Preferably, the nucleic acid sequences mentioned above are chosen from deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequences, more preferentially chosen from vector-vectorized DNA or RNA sequences. of gene therapy such as viral vectors selected from adenoviral vectors (DNA viruses), retroviral vectors (RNA virus), adeno-associated virus derived vectors or AAV (Adeno Associated Virus) and vectors derived from other viruses (such as Herpes Simplex Viruses (HSV), poxviruses, influenza viruses) and non-viral vectors such as polycations or nanoparticles (particularly hydroxyapatite or modified hydroxyapatite (such as poly- L-lysine (PLL) -modified hydroxyapatite)) and interfering RNA sequences (pARNi or siRNA for "small interfering RNA") or double-stranded RNA (dsRNA). The nucleic acid sequences are preferably chosen from native or modified sequences or part of the native or modified sequences of the gene coding for the p53 protein, for the Rb protein (in particular the Rb1 gene) or for the gene coding for the interleukin 12 (IL-12) or their respective transcripts (ie in the form of RNA). The commercial form of these anti-cancer agents is most often the freeze-dried form or the powdered form (i.e. in powder form). These lyophilizates or powders of anticancer agents may contain the excipients conventionally used in the pharmaceutical field: lactose (solubilizing and lyophilizing agent), methyl parahydrobenzoate (antioxidant) and / or sodium chloride (NaCl). For the purposes of the present description, the term "particles containing an iron compound" means particles comprising or consisting of an iron compound, generally comprising iron (III), generally an oxide or hydroxide of iron. We often talk about Ultra Small Particles of Iran Oxide or USPIOs.
    [0026] As a rule, the magnetic particles are composed in whole or in part of iron hydroxide; hydrated iron oxide; ferrites; mixed iron oxides such as mixed iron oxides of cobalt, nickel, manganese, beryllium, magnesium, calcium, barium, strontium, copper, zinc or platinum; or a mixture of these. According to a particularly preferred variant, the magnetic particles are superparamagnetic.
    [0027] The magnetic particles before being coated with the appropriate coating then preferably have a crystalline diameter of 5 to 200 nm, more preferably 10 to 60 nm or 10 to 20 nm.
    [0028] In an advantageous embodiment, the magnetic particles based on an iron compound are covered by a hydrophilic compound, preferably of the polyethylene glycol (PEG) type, more preferably a PEG with a molar mass of from 1500 to 3000.
    [0029] In another advantageous embodiment, the magnetic particles based on an iron compound are covered by an unsaturated fatty acid, preferably monounsaturated, more preferably by oleic acid (C 18: 1 n-9 ). The magnetic particles thus rendered fat-soluble are suspended in the continuous lipid phase.
    [0030] For the purposes of the present application, the term "ferrite" denotes iron oxides of general formula [x Fe2O3, y MO], where M denotes a magnetizable metal under the effect of a magnetic field such as Fe, Co, Ru, Mg, Mn, the magnetizable metal possibly being radioactive.
    [0031] Preferably, the magnetic particles of the compositions of the invention comprise a ferrite, in particular maghemite (Fe2O3) or magnetite (Fe3O4), or else mixed ferrites of cobalt (Fe2COO4) or of manganese (Fe2MnO4). In this context, the magnetic particles composed in whole or in part of a ferrite, and preferably substantially (that is to say more than 90%, preferably more than 95%, more preferably more than 98%, are particularly preferred). by weight), maghemite or magnetite or a mixture thereof. Preferably, the radioactive microspheres mentioned above consist of a cation exchange resin (comprising, for example, a polyvinyl alcohol or a copolymer comprising styrene and divinyl benzene such as Aminex 50W-X4 from the company Biorad) labeled with Yttrium 90 (SIR-Spheres® marketed by SIRTeX Medical Ltd) or are made of glass in which yttrium 90 has been incorporated (TheraSphere® marketed by BTG) or consist of a polymer such as polylactic acid (PLLA) and one of the radioelements mentioned above, the holmium (166Ho) then being the preferred radioelement. More preferably, it is yttrium in the form of 89Y203 which is incorporated into the microspheres made of glass, which are then irradiated with neutrons to render them radioactive by transforming 89Y cold Yttrium into radioactive Yttrium 90Y. Even more preferably, the microspheres consisting of a cation exchange resin or consisting of glass have a diameter of 20 to 60 μm and 20 to 30 μm, respectively. The microspheres of the SIR-Spheres type have in particular been the subject of patent EP 0 740 581 B1.
    [0032] Surfactant It is recalled that the term "surfactant" or "surfactant" refers to a compound with an amphiphilic structure which gives it a particular affinity for water / oil type interfaces which gives it the capacity to lower the energy free of these interfaces and stabilize dispersed systems. The composition according to the invention comprises at least one surfactant of formula (I) as defined above. It may therefore comprise a surfactant of formula (I) or a mixture of surfactants of formula (I).
    [0033] The surfactant has the formula (I) as defined above, preferably in which s is 0 or 1, m represents an integer of 2 to 10 and R 1 represents a group of formula (II) as defined above. wherein n is an integer of 5 to 7, o is an integer of 1 to 3, p is an integer of 3 to 5, q is an integer of 2 to 5 and r is 0 or 1. Even more preferably, in the formula (I) as defined above, s is 1, m represents an integer of 2 to 5 and n is 7, o is 1, p is 5 and q is an integer from 2 to 4 and r is 1 in formula (II) which represents R1. HLB (meaning Hydrophilic-Lipophilic Balance, or hydrophilic / lipophilic balance) is a size, well known to those skilled in the art, characteristic of a surfactant. Preferably, the surfactant according to the invention is a surfactant with a low HLB, that is to say a surfactant having an HLB value of from 1 to 8, preferably from 1 to 6.
    [0034] Advantageously, the surfactant of formula (I) is soluble in iodinated oil and this, in particular in the ranges of proportions indicated above. Advantageously, the surfactant of formula (I) according to the invention is chosen from polyglycerol polyricinoleate and PEG-30-dipolyhydroxystearate. Polyglycerol polyricinoleate or PGPR (Palsgaarde4125 or Palsgaarde4150) is a surfactant having, as hydrophilic group, poly-glycerol (preferably consisting of at least 75% of di and tri-glycerol and at most 10% of heptaglycerol) and hydrophobic group of inter-esterified ricinoleic fatty acids. He has a HLB of 1.5. It corresponds to a surfactant of formula I, as defined above, in which: s is 1, m represents an integer of 2 to 5, R 1 represents a group of formula (II) as defined above in where n is 7, o is 1, p is 5, q is 2 to 4 and r is 1, - R2 is R1 and / or a hydrogen atom. Preferably, the surfactant of formula (I) is a mixture of surfactants of formula (I) in which: s is 1, m is 2, 3, 4 or 5, R 1 represents a group of formula (II) as defined above wherein n is 7, o is 1, p is 5, q is 2, 3 or 4 and r is 1, R 2 is R 1 and / or hydrogen. Preferably, the surfactant of formula (I) according to the invention is a mixture of surfactants chosen from compounds of formula: -OH-OH and OH PEG-30-dipolyhydroxystearate (Cithrol® DPHS and formerly Arlacel® P135 sold by Croda) has a HLB of 5-6. The PEG designation is in accordance with the nomenclature conventions set forth by the INCI, the value specified above being the average number of monomer units of ethylene oxide. It corresponds to a surfactant of formula I, as defined above, in which: s is 0, m is 30, R1 represents a group of formula (II) as defined above in which n is equal to 9, o is 1, p is 5, q is 7 and r is 0, R2 is the same as R1.
    [0035] Use of the Composition According to a Second Object, the invention relates to the use of the composition as defined above for vectorizing an anticancer agent. The invention also relates to a composition in the form of an emulsion as defined above, for its use in the treatment of cancer or its metastases, preferably by intraarterial chemoembolization. In an advantageous embodiment, the invention relates to the use of a composition according to the invention for the preparation of a medicament for the treatment of cancer or its metastases, preferably by intraarterial chemoembolization. Intra-arterial chemoembolization is defined as the percutaneous intra- arterial introduction of a substance to occlude a blood vessel in combination with an anticancer agent to deliver a therapeutically effective amount of this agent to a tumor. Preferably, the cancer thus treated is chosen from liver cancer (in particular primary cancer of the liver such as hepatocellular carcinoma or HCC), cholangiocarninoma, hepatic metastases of primary cancers chosen from colorectal cancer, neuroendocrine tumors and cancers. breast cancer, kidney cancer and melanoma. The chemoembolization of a hepatic tumor is carried out, preferably, by the implementation of the following successive steps: a) percutaneous catheterization from the femoral artery, b) administration of the emulsion according to the invention up to stasis in the second or third order branches is observed; c) optionally, administration of an embolizing agent in the tumor after the emulsion has been administered.
    [0036] Preferably, the emulsion according to the invention thus administered does not comprise more than 20 ml of iodinated oil, more preferably not more than 15 ml of iodized oil. Catheterization, which involves bringing a tube, called a catheter, into the hepatic artery and into the branch of this artery which perfuses the cancerous lesion, is advantageously performed with the assistance of an imaging technique. Guidance software is also available to interventional radiologists to enable them to place their catheters as optimally as possible. By "embolizing agent" is meant one or more compounds to slow down or permanently or temporarily stop the flow of blood into a vessel. As an example of "embolizing agent", mention may be made of gelatin sponge, gelatin foam particles (Gelfoam®, Spongel®, Curaspon®), polyvinyl alcohol (PVA) or calibrated microspheres based on, for example trisacrylgelatin, PVA (Ivalon®, Contour®), etc ...
    [0037] Advantageously, before the chemoembolization procedure, angiography or arteriography, performed using a CT angiogram or MR angiography (Magnetic Resonance Angiography or MRA) and most often an injection of contrast medium (by for example, for CT angiography: water-soluble iodinated contrast media such as iobitridol (Xenetix®) or iohexol (Omnipaque®), and for angioMR: gadolinium chelates such as gadoteric acid (Dotarem® ) or gadobutrol (Gadovist®)) is used to identify visceral vasculature and arterial perfusion of the tumor (s).
    [0038] This chemoembolization technique can be used alone or in combination with one or more of the other techniques mentioned below. It can also be substituted for one of these other techniques. In the case where the anticancer agent is selected from radioelements or complexes of radioelements with macrocyclic chelates mentioned above, the technique used is internal selective radiotherapy or radioembolization. It consists in injecting the composition according to the invention directly into the branch of the hepatic artery which perfuses the tumor. This technique has the advantage of delivering a very important irradiation to the tumor without significantly irradiating the healthy liver and other organs of the patient. In the case where the anti-cancer agent is selected from magnetic particles based on an iron compound (USPI0s), the technique used is ablative magnetic hyperthermia. This consists in inducing a local rise in temperature in the tumor tissue, the tumor cells being more sensitive to a rise in temperature than healthy cells. This rise in temperature is caused by the use of an external stimulus and in particular the application of an alternating magnetic field to the area to be treated. There are two types of hyperthermia depending on the temperature reached: for temperatures above 46 ° C, it is possible to induce tissue necrosis and it is called thermoablation; temperatures of 42 ° C to 46 ° C alter the functions of many structural and enzymatic proteins, altering cellular development and differentiation, and may induce apoptosis, referred to as moderate hyperthermia. If the cells do not die, they become more sensitive to ionizing radiation or chemotherapy.
    [0039] In the case where the anti-cancer agent is a nucleic acid sequence chosen from deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequences vectorized by a viral vector or a non-viral vector as mentioned above. above or an interfering RNA sequence (pARNi or siRNA for "small interfering RNA") or double-stranded RNA (dsRNA), the technique used is gene therapy, sometimes also called "gene therapy". The principle of this approach is to introduce a foreign gene whose expression product induces (directly or directly) the death of tumor cells. Schematically, three approaches are usable: a) the induction of an immune defense ("immunostimulation") by modifying the antigens of the membrane of the tumor cells; b) the transfer of a "tumor suppressor" gene into the genome of the tumor cell, or finally c) the transfer of a so-called "suicide" gene that makes it possible to transform a non-active anti-cancer agent prodrug into a molecule toxic to tumor cells. All these different techniques are known to those skilled in the art. The latter will easily choose the parameters to adjust to implement these techniques using the composition according to the invention. The terms "treat" and "treatment", unless otherwise indicated, mean any action to improve the comfort, well-being and survival of an individual, so this term covers both alleviate, diminish, relieve and cure. . Preparation of the emulsion composition according to the invention The emulsion composition is preferably prepared extemporaneously.
    [0040] The invention also relates to a process for preparing a composition in emulsion form as defined above, comprising the following steps: a) Mixing of the surfactant of formula (I) as defined above in the oil iodine, and b) mixing the solution obtained in step a) with an aqueous solution comprising an anticancer agent. The aqueous solution mixed with the solution obtained in step a) may further comprise a densifying agent as defined above.
    [0041] The mixing performed in step b) can be carried out by any means known to those skilled in the art. Preferably, a three-way valve is used. The iodinated oil comprising the surfactant is placed in a first syringe which is attached to the three-way valve. The aqueous solution comprising the anti-cancer agent is placed in a second syringe also attached to this three-way valve at 90 °.
    [0042] By pressing alternately on the pistons of the two syringes (preferably 20 to 35 times), a mixture of the two phases is performed. The third tap route allows a selectively advanced, fluoroscopically controlled catheter to be attached to the tumor lesion for administration of the emulsion.
    [0043] Forms for marketing the composition according to the invention The invention also relates to a kit comprising: a surfactant of formula (I) as defined above, an iodinated oil, an anticancer agent, as combination products for simultaneous use , separated or spread over time for use in the treatment of cancer. The surfactant, the iodinated oil and the anticancer agent (generally solubilized in an aqueous solution) are in three different containers. Generally, the mixture of [surfactant / iodized oil / anticancer agent in aqueous solution] leads to the composition in emulsion form according to the invention. In addition, the invention relates to a kit comprising: a composition comprising the surfactant of formula (I) as defined above and an iodinated oil, an anti-cancer agent, as combination products for simultaneous, separate or spread use in the time for its use for the treatment of cancer. The composition and anticancer agent (generally solubilized in an aqueous solution) are in two different containers. Preferably, the composition consists of a mixture of surfactant of formula (I), an iodinated oil and optionally a non-iodinated oil. Generally, the mixture of the composition and the anticancer agent in aqueous solution leads to the composition in emulsion form according to the invention.
    [0044] The invention also relates to the use of a kit comprising: a surfactant of formula (I) as defined above, an iodinated oil, as combination products for vectorizing an anticancer agent. The surfactant and the iodized oil are in two different containers.
    [0045] By "container" is meant any pharmaceutically acceptable container that may contain a product. By way of example, mention may be made of an ampoule, a vial, a pre-filled syringe.
    [0046] By "pharmaceutically acceptable container" is meant any container that does not interact with the product, preferably any container that does not release compounds into the iodized oil and does not degrade the iodized oil. The examples given below are presented for illustrative and non-limiting purposes of the invention. Figure 1: Plasma kinetics of doxorubicin in rats with hepatocellular carcinoma after chemoembolization (TACE) injection of several emulsions.
    [0047] EXAMPLE 1 1. Preparation of emulsion compositions according to the invention: 1.1. Emulsions of Lipiodole and Anthracycline 50 mg doxorubicin (Adriblastine®) were reconstituted in 2.5 mL of Xenetix® 250 (250 mg iodine / mL). After manual stirring for 30 seconds for good dissolution, the solution obtained was taken with a syringe 20mL luer lock. This syringe was then placed on a three-way valve.
    [0048] PGPR (1% w / v total, 100 mg - Interchim) was dissolved in 7.5 ml of Lipiodol® by manual shaking. The resulting oil was removed with a 20 mL luer lock syringe which was also placed on the three-way valve at 90 ° C. 34 passages, or 17 medium-force round trips were made starting with the water in the oil. For these emulsions, the volumes of the aqueous phase and the lipid phase chosen were respectively 2.5 ml (25% v / v) and 7.5 ml (75% v / v). The aqueous phase / lipid phase ratio was 1/3. Other emulsions have been performed: - by replacing doxorubicin as an anticancer agent with idarubicin (Zavedos®), mitomycin C (Kyowa) or epirubicin (Farmorubicine®), and / or do not use a densifying agent, or replace the Xenetix® 250 densifying agent with Xenetix® 300 (300 mg iodine / mL) or lopamiron®, or - by replacing the PGPR surfactant with CithrolTM DPHS (PEG -30 Dipolyhydroxystearate), or - by changing the proportion of surfactant. For CithrolTM DPHS, solubilization was achieved by the use of ultrasound (Vial tweeter, 3x45s).
    [0049] Verification of the direction of the emulsion: Once the emulsion has been made, the meaning of the emulsion has been verified by a simple visual test. Two vials were prepared: one with aqueous phase (Xenetix® 250 or Xenetix® 300 if applicable) and the other with iodized oil (Lipiodol®). A drop of freshly prepared emulsion was added in each of the two bottles. The drop was dispersed in the vial of Lipiodol® and did not disperse in the vial of Xenetix®, so we had a W / O (water-in-oil) emulsion.
    [0050] The red doxorubicin droplets were clearly visible in a yellow background of oil. The size of the aqueous phase droplets was evaluated using an optical microscope. The main emulsions produced are described in the following table: Nature number of the surfactant used Proportion of surfactant used (`) / 0 m / v) Nature of the anti-cancer agent used Nature of the densifying agent used Size of the droplets of phase aqueous Visual stability observed * product El PGPR 1% Doxorubicin lobitridol ** 5 - 20 lm No phase shift at 24 h E2 PGPR 1% Doxorubicin None 5 - 40 lm Phase shift <5% at 24h E3 PGPR 1% Doxorubicin lobitridol *** 5 - 20 lm No phase shift at 24h E4 PGPR 1% Doxorubicin lopamidol ** ** 5 - 10 lm No phase shift at 24h E5 PGPR 0.5% Doxorubicin lobitridor 5 - 20 lm E6 PGPR 0.3% Doxorubicin lobitridol ** 5 - 20 lm E7 PGPR 1% Mitomycin C lobitridol ** 5 - 10 lm No phase shift at 24 h E8 PGPR 1% Epirubicin lobitridol ** 5 - 20 lm E9 PGPR 0.7% Idarubicin lobitridol ** 2 - 10 lm El 0 Cithrol® DPHS 1% Doxorubicin None 5 - 20 lm Phase shift <5% at 24h Ell Cithrol® DPHS 1% Doxorubicin lobitridol ** 5 - 20 lm No phase shift at 24 hours E12 Cithrol® DPHS 1% Doxorubicin lobitridol *** 5 - 20 lm * at room temperature (20 ° C) 10 ** Xenetix® 250 *** Xenetix® 300 **** lopamiron® 250 These different emulsions prepared using a surfactant of formula (I) and different anticancer agents have all demonstrated a stability as expected. 1.2. Emulsions of Lipiodol® and radioelements 1.2.1. Emulsion of Lipiodol® and 90YCI3 To a radioactive solution of Yttrium 90 in the form of an acid solution (Yttrium chlorite, 0.05M HI) was added a buffer solution (Tris) in order to bring the resulting solution to a pH compatible with use in the patient (6 <pH <9). The solution obtained can be diluted in a volume of saline so that the final volume does not exceed 10 ml. 1% (w / v) of PGPR was dissolved in 10 mL of Lipiodol® according to the technique described above. The lipid phase consisting of 10 ml of Lipiodol® and 1% of PGPR was then added to the aqueous phase and the emulsion was prepared by stirring by suction and resuspension of the suspension thus obtained. 1.2.2. Emulsion of Lipiodol® and 90YCI3 Complexed with DOTA The radioactive solution was added to a solution of DOTA (1,4,7,10-tetraazacyclododecane-N, N ', N ", N"' - tetraacetic acid) in a buffer. at pH 6-7 and the medium was heated at 80 ° C for 30 min. To this solution was added a volume of saline so that the final volume did not exceed 10 ml. 1% (w / v) of PGPR was dissolved in 10 mL of Lipiodol® according to the technique described above.
    [0051] The lipid phase consisting of 10 ml of Lipiodol® and 1% of PGPR was then added to the aqueous phase and the emulsion was prepared by vigorous stirring of the suspension thus obtained. 1.3 1.3. Emulsion of Lipiodol® and iron-based magnetic particles 1.3.1. Emulsion of Lipiodol®, Magnetic Particles Based on Iron and Anthracycline Magnetic nanoparticles based on an iron compound coated with oleic acid (synthesized according to techniques known from the state of the art) were solubilized totally in 60 g of Lipiodol® at 60 ° C for 24 h. The total solubilization of said magnetic nanoparticles was visually appreciated by noting the absence of aggregate visible to the naked eye. After returning to room temperature, the solution was stored or used to make emulsions. One vial of Adriblastine® 50 mg was reconstituted with 2.5 mL of Xenetix® 250. Manually shake 30 seconds for good dissolution. The solution obtained was taken with a 20 mL luer lock syringe which was placed on a three-way stopcock. PGPR (1% w / v total, 100 mg) was dispersed in 7.5 mL of Lipiodol® including the magnetic particles.
    [0052] The oil obtained was taken with a 20 mL luer lock syringe which is also placed on the three-way valve. 30 passages, ie 15 medium-force roundtrips were made starting with the water in the oil. 1.3.2. Emulsion of Lipiodol® and magnetic particles based on iron Magnetic nanoparticles based on an iron compound (synthesized according to known techniques of the state of the art: see in particular W02004 / 058275) coated with a layer gem-bisphosphonate of formula: ## STR5 ##, coupled to PEG 2000, were solubilized completely in 10 g of physiological saline at room temperature. 60 ° C for 24 hours to obtain an iron concentration of 0.5M. The total solubilization of said magnetic nanoparticles was visually appreciated by noting the absence of aggregate visible to the naked eye. After returning to room temperature, the solution was stored or used to make emulsions. 2.5 ml of the resulting solution was taken with a 20 ml luer lock syringe which was placed on a three-way stopcock. PGPR (1% w / v total, 100 mg) was dispersed in 7.5 ml of Lipiodol®. The oil obtained was taken with a 20 mL luer lock syringe which was also placed on the three-way 90 ° valve. 30 passages, ie 15 medium-force roundtrips were made starting with the water in the oil. 2. Comparison with emulsions not in accordance with the invention Emulsions according to the same protocol as that specified in section 1.1 or a slightly different protocol (the differences with respect to the protocol of paragraph 1.1 are indicated in the table below: respective volumes of the aqueous and lipid phases are calculated from their ratio), were prepared using either a concentration of PGPR not according to the invention, or surfactants with low or high HLB as surfactants of the Span® family fatty acid esters of sorbitan), high HLB surfactants from the family Cremophor® (glycerol polyethylene glycol ricinoleate), the family Tween ° (polyoxyethylene of fatty acid esters and sorbitan) or the family Pluronics ° (block copolymers based on ethylene oxides and propylene oxide sold by BASF) and the surfactant CITHROL ° PG32IS HLB low (HLB = 6.7).
    [0053] Other densifying agents such as nonionic iodinated contrast media have been tested, such as PVP (polyvinylpyrrolidone), glycerol, or dextran T40 (Sigma), but the maximum quantities that can be used do not allow the density to be approached. an iodized oil like Lipiodol®. The ioxaglic acid (Hexabrix®) does not allow easy solubilization of anticancer agents such as doxorubicin and significantly increases the osmolality of the composition.
    [0054] The main emulsions produced are described in the following tables: Emulsions prepared with a surfactant according to the invention but using a non-compliant concentration Nature number of the surfactant used Proportion of surfactant used Nature of the anti-cancer agent used Ratio aqueous phase / phase lipid droplet size Observations product E13 PGPR 0.2% Doxorubicin 1/3 Heterogeneity: - Emulsion mass per 50 mg in 2.5 small drops E / H relative to the mL of and more - Phase shift total volume Xenetix® 250 large 20 - 50 lm of emulsion E13 'PGPR 0.2% Doxorubicin 1/3 Heterogeneity: - Emulsion mass per 50 mg in 2.5 small drops E / H compared to the mL of serum and more - Phase shift total physiological volume 20 to 50 μm thick of the emulsion Emulsions prepared with a surfactant and / or a densifying agent not in accordance with the invention and / or in non-co-aqueous phase / lipid phase ratios Number of Nature Proportion of Nature of Ratio aqueous phase Size of Observations product surfactant used surfactant agent / droplet phase used in anti-cancer used lipid mass relative to the total volume of emulsion E14 Span "80 1% 2 mL d one-quarter aggregates - Emulsion droplet solution 50-100 lm E / H doxorubicin 50 mg in - phase shift 10 mL Xenetix® 250 E15 * Span "80 1% 2 mL 1/4 Heterogeneity: small drops - W / O emulsion solution and more - Doxorubicin phase shift 50 mg in 20 - 50 lm fat 10 ml of physiological saline supplemented with dextan T40 at 2.5 g / 50 mL E16 * Cremophor "EL 0.5% 2 mL of a 1/4 2 - 5 lm - D / H doxorubicin solution emulsion 50 mg in - Phase shift 10 mL of physiological saline supplemented with dextran T40 at 3 g / 50 mL E17 Tween80 0.1% Doxorubicin 1 / 1 10 lm - Emulsion (50 mg in H / E mL of - Light Xenetix® dephasing at 250) 24h E18 * 0.1% Tween80 or Doxorubicin 1/1 10 - 100 lm O / W emulsion 0.01% (50 mg in 5 ml physiological saline supplemented with Tween® 80 and 1% PVP) E19 * Tween 80 0.01% Doxorubicin 1/1 100 - 300gm - HCI Emulsion in 5 H / E mL of - immediate dephasing glycerol at 2.5% E20 CITHROC 1% Doxorubicin 1/3 Not measurable - Emulsion PG32IS 50 mg in W / H 2.5 mL - Instantaneous and violent phase shift Xenetix® 250 * emulsion prepared with a densifying agent not according to the invention: PVP (polyvinylpyrrolidone), Dextran T40, ioxaglic acid (Hexabrix®) or glycerol Emulsions prepared without surfactant and / or without a densifying agent Nature number of the agent Ratio phase Sizes of Observations anticancer product used aqueous / lipid phase droplets E21 * Doxorubicin (50 mg 1/1 10 lm O / W emulsion in 5 mL saline) E22 Doxorubicin (50 mg 1/1 10 pm O / W emulsion in 5 mL of Xenetix ® 250) E23 * Doxorubicin (50 mg 1/3 or 1/2 Not measurable (greater than 200 lm) - W / O emulsion - Phase shift immediately in 2.5 mL of Xenetix® 250) E24 * Doxorubicin (50 mg 1/4 10 μm - O / W emulsion - very emulsion in 3 mL of saline) viscous and thick: not usable in a clinical setting. E25 Epirubicin (50 mg 1/1 10 pm O / W emulsion in 5 mL of lopamiron® 250) E26 * Epirubicin (50 mg 1/1 10-20 μm O / W emulsion in 5 mL of physiological saline) * emulsion prepared without densifying agent Span® 80 (Croda) is sorbitan monooleate. Tween® 80 (Croda), also called polysorbate 80, is PEG-20 sorbitan monoleate. Cremophor® EL (BASF) has the chemical name: Polyoxyl 35 Castor Oil. CITHROL PG32IS is polyglyceryl-3-diisostearate. It is therefore not branched as the surfactants of formula (I).
    [0055] Other Span® than Span® 80 (HLB = 4.3) were tested: Span® 20 (HLB = 8.6), Span® 65 (HLB = 2.1), Span® 83 (HLB = 3) , 7), Span® 85 (HLB = 1.8). The emulsions prepared with these surfactants all phase out immediately after their preparation. The tests carried out with Pluronic® compounds (BASF) were also inconclusive since it was not possible to carry out an emulsion with these compounds. Thus, all the comparative emulsions obtained presented either insufficient stabilities or a direction not in accordance with the invention. 3. In vivo evaluation of the emulsions according to the invention and comparison with emulsions not in accordance with the invention 3.1. Materials and Methods Animal Model: The tumor induction method described in Garin et al. (Lab Anim 2005 Jul; 39 (3): 314-20) was used on Sprague-Dawley rats (Depré or January supplier, France), previously anesthetized. 6.106 N1-S1 tumor cells (deposited at ATCC as CRL-1604TM also referred to as Novikoff cells) of rat hepatocellular carcinoma suspended in 100 μl of IMDM medium (Iscove's Modified Dulbecco's Medium) were administered under the hepatic lobe capsule. left of rats, by slow injection in about 50 seconds. By way of information, the tumor cell line N1-S1 was initially obtained from an induced hepatoma by oral administration of 4-dimethylaminoazobenzene in a male Sprague-Dawley rat. 8 groups of 4 animals each have been formed. Products tested (one product per group): Compositions according to the invention Products Nature and quantity of Nature and proportion of Agent tested the anti-cancer agent surfactant used densifier used used El 0.5 mg doxorubicin * 1% (m / v) of PGPR Yes (25 1..1L Xenetix® 250) E2 0.5 mg doxorubicin * 1% (w / v) PGPR No E4 0.5 mg epirubicin ** 1% (w / v) PGPR Yes (25 1..1L Xenetix® 250) E11 0.5 mg doxorubicin * 1% (w / v) CithrolTM DPHS Yes (25 1..1L Xenetix® 250) * doxorubicin (Adriblastine®, Pfizer) ** epirubicin (Farmorubicine®, Pfizer) The ratio between the aqueous phase and the lipid phase was 1/3 (25 μL of aqueous phase and 75 μL of Lipiodol®). The four emulsion compositions tested were inverse emulsions (W / O). Compositions not in accordance with the invention (without surfactant) Products Nature and quantity of Agent Ratio Phase Sens of testing the anticancer agent aqueous densifier / emulsion used used lipid phase E21 0.5 mg of doxorubicin * No 1/1 H / E E22 0.5 mg doxorubicin * Yes (50 μL of Xenetix® 250) 1/1 H / E E23 0.5 mg doxorubicin * No 1/3 W / H doxorubicin (Adriblastine, Pfizer) Control Products doxorubicin alone (NaCl 0.9%) or, if appropriate, epirubin alone, was injected as a control into one of the groups of 4 rats. Product Administration: These methods are well known to the person skilled in the art who will therefore be able to adjust certain parameters himself if this proves necessary. The day before the TACE procedure (D-1), the animals were imaged on the MRI (Bruker, 2.35 T) in order to check the tumor growth. On the day of the TACE (JO) procedure, rats were again imaged to measure the size and volume (using image processing software) of liver tumors before treatment. 7 days after having implemented the tumor induction method, the products (volume: 100 μL) were injected, via the gastroduodenal artery, to the animals previously anesthetized.
    [0056] Measurement of the plasma kinetics of the anti-cancer agents contained in these emulsions after their injection: Blood samples of 300 μl at time 0, 5, 10, 20, 30 and 45 minutes after intra-arterial injection were made after catheterization of the carotid artery. 150 μl of plasma after centrifugation were then recovered and heparinized for the determination of anticancer agents. A study of the plasma kinetics of the anticancer agent was thus carried out.
    [0057] Plasma dosing of doxorubicin was performed in heparinized spleen plasma by high performance liquid chromatography (or HPLC) equipped with a fluorescence detector. Plasma samples were prepared by acid precipitation (ammonium acetate pH 3.5) with 40% acetonitrile. 200 μl of rat plasma (lithium heparin) was needed. 200 μl of the extract were analyzed in reverse phase HPLC on a ZORBAX 300SB-C18 4.6 x 150mm column, 3.5 μM and fluorimetric detection (480 nm excitation wavelength, emission wavelength 560 nm).
    [0058] The analysis was carried out in 30 minutes with a gradient of 5 mM ammonium acetate pH3.5 / acetonitrile. The samples were assayed via a calibration curve (DOX calibration range from 2 μg / L to 1600 μg / L - DOXoI calibration range from 2 μg / L to 400 μg / L). When the area of the HPLC peak was greater than the upper limit of quantification 1..11_ was injected instead of 1..11_ to obtain a doxorubicin area within the range. The assays were performed blind at TO times, 5 min, 10 min, 20 min, 30 min and 45 min. Histological Evaluations of Tumor Samples and Healthy Liver: The animals were euthanized by gaseous anesthesia with isoflurane (5%) with 1 L / min of O 2. An autopsy and blood, plasma, tumor and healthy liver samples were taken to perform dosages of doxorubicin and epirubicin. Tumor and healthy liver samples were frozen (non-fixed) for histological analysis of the tumor. After treatment (sections, fixation for H & E ...) slides on which samples were placed samples, H & E (hematoxylin-eosin) staining was performed to better differentiate the tumor part of its healthy liver environment. Fluorescence measurements specific for the presence or absence of doxorobucin were performed and fluorescence levels were indicated on a scale of 1 (weak fluorescence) to 6 (strong fluorescence). This fluorescence is proportional to the amount of doxorubicin present in the tissue in question. All these techniques are well known to those skilled in the art. 3.2. Results achieved 3.2.1. Plasma kinetics of anti-cancer agents The following points can be seen on the graph of Figure 1 representing the averaged concentrations as a function of time: The peak concentration of doxorubicin is at 5 minutes for the eight groups of animals. The highest peak is for injection of doxorubicin alone (Doxorubicin Control) with an average of 2447 pg / L. It is followed by the group that received the product E22 (emulsion sense H / E - ratio 1/1 with Xenetix® 250 without surfactant) for which the average peak concentration is 1287 pg / L, a value almost twice as much low than that obtained for the injection of doxorubicin alone and then of the group having received the product E23 (emulsion E / H sense - ratio 1/3 without surfactant or densifying agent) and then of the group having received the product E21 (emulsion direction H / E - ratio 1/1 without surfactant or densifying agent). Between the 10 and 45 min sampling times, the groups receiving doxorubicin alone and the E21, E22 and E23 products follow the same decrease with lower values for the groups that received products E21, E22 and E23 (at 45 min , "Doxorubicin Control Only" group = 112 pg / L, "E21" group = 106 pg / L, "E22" group = 63 pg / L and "E23" group = 143 pg / L).
    [0059] For the groups which received the products El (emulsion direction W / H - 1/3 with Xenetix® 250 with PGPR as surfactant), E2 (emulsion direction W / H with PGPR, without densifying agent), E4 (emulsion sense E / H with epirubicin, PGPR and Xenetix® 250) and El 1 (emulsion sense W / H with doxorucin, CithrolTM DPHS and Xenetix® 250), the concentration of doxorubicin is much lower, and this at all sampling points, that of groups receiving doxorubicin alone or products E21, E22 and E23. The analysis of the plasma kinetics shows that there is no plasma peak after injection of the compositions according to the invention E1, E2, El 1 (FIG. 1) and E4 (results not shown in FIG. 1). Tested products Concentration Percentage of plasma decrease in anti-cancer agent 5 minutes after plasma injection (in μg / mL) of the anti-cancer agent at 5 minutes after injection of the emulsion compared to intra-arterial injection the anticancer agent alone. El 49 97.8% E2 125 94.4% E4 64 97.1% Ell 73 96.7% Doxorubicin control 2447 only * * Epirubicin control only for emulsion E4 Thus, for rats that have received stable emulsions E According to the invention, a reduction of more than 94% in the plasma doxorubicin level compared with animals receiving only doxorubicin alone. For the rats having received the emulsions E21, E22 and E23 which are not in accordance with the invention, a plasma peak is observed 5 minutes after injection thereof. Products tested Plasma concentration Percentage decrease in anti-cancer agent 5 minutes after injection (in μg / mL) of plasma concentration of anti-cancer agent at 5 minutes after injection of the emulsion compared to intra-arterial injection on the anticancer agent alone. E21 914 59.3% E22 1287 42.7% E23 1035 53.9% Doxorubicin control only 2447 Thus, for the rats which have received the emulsions not conforming to the invention, a reduction of at best 59% in the rate of plasma doxorubicin compared with animals receiving only doxorubicin alone.
    [0060] The direction of the W / O emulsion and the stability of this improved by the use of a surfactant of formula I (PGPR or PEG-30-dipolyhydroxystearate) make it possible to envisage an effective clinical use of a composition according to the invention. 3.2.2. Histological evaluations of tumor samples and healthy liver The analysis of the slides, in particular the H & E stains, demonstrated the presence of a tumor of the type CHC (contiguous polygonal cells in dense and thick cords) in all the animals implanted with N1S1 cells well delineated relative to healthy tissue. The fluorescence measurement was performed using a Nikon Eclipse 80i ABS microscope equipped with a Nikon lntensilight C-HGFI precenter fiber fiber system. The images were viewed using Hamamatsu NDP.view 2.5 visualization software. Autofluorescence of the tissues was determined on sections of the control animals. This level of fluorescence is deduced from the fluorescence levels observed for the samples of tumor and healthy liver of the animals having received the emulsion compositions. This measurement on these sections revealed differences in the amounts of doxorubicin at the level of the tumor with, in the order of the classification carried out (blindly determined): El (score 6), E21 (score 1), E22 (score 3 ) and E23 (score 2).
    [0061] The emulsion E1 thus makes it possible to maintain the anticancer agent at the tumor level much more than the emulsions not in accordance with the invention do. The emulsion compositions according to the invention demonstrate their great ability to vector anticancer agents since they allow these agents to remain in the tumor and not leave the vascular compartment.
    权利要求:
    Claims (13)
    [0001]
    REVENDICATIONS1. Composition comprising an iodinated oil and at least one surfactant of formula (I): wherein: s is 0 or 1, m represents an integer of 2 to 30, R1 represents a group of formula (II) wherein n represents an integer from 4 to 10, o represents an integer from 1 to 4, p represents a number integer from 3 to 7, q represents an integer from 2 to 10 and r is 0 or 1, R2 represents a hydrogen atom or is the same as R1.
    [0002]
    2. Composition according to claim 1, characterized in that it is a stable water-in-oil emulsion and in that it comprises: - from 20 to 40% (v / v) of aqueous phase, in the form of droplets , comprising an anti-cancer agent, - from 60 to 80% (v / v) of lipid phase comprising an iodized oil and at least one surfactant of formula (I) as defined in claim 1 in a proportion by weight of surfactant per relative to the total volume of the composition, from 0.3 to 5%.
    [0003]
    3. Composition according to Claim 2, characterized in that the anti-cancer agent is chosen from anthracyclines, platinum complexes, mitoxantrone, nemorubicin, mitomycin C, bleomycin, irinotecan, 5-Fluoro-Uracil. , sorafenib, regorafenib, brivanib, orantinib, linsitinib, erlotinib, fotemustine, cytosine C, cyclophosphonamide, cytosine arabinoside, paclitaxel, methotrexate, everolimus, PEG-arginine deiminase , combinationgafur / gimeracil / oteracil, muparfostat, peretinine, gemcitabine, bevacizumab, and ramucirumab, radioelements and complexes of said radioelements with macrocyclic chelates, magnetic particles based on an iron compound, nucleic acid sequences selected from deoxyribonucleic acid and ribonucleic acid sequences and a mixture thereof.
    [0004]
    4. Composition according to the preceding claim, characterized in that the anthracyclines are chosen from doxorubicin, epirubicin, nemorubicin and idarubicin.
    [0005]
    5. Composition according to any one of claims 2 to 4, characterized in that the aqueous phase further comprises a densifying agent selected from nonionic iodinated contrast media and a mixture thereof.
    [0006]
    6. Composition according to any one of claims 2 to 5, characterized in that the lipid phase further comprises a non-iodized oil selected from linseed oil, soybean oil, palm oil, coconut oil, castor oil, corn oil, cottonseed oil, peanut oil, sesame oil, sunflower oil, safflower oil, oil almond oil, olive oil, poppy oil and an oil comprising or consisting of a mixture of fatty acid triglycerides of the formula: where R is an aliphatic chain comprising from 3 to 35 carbon atoms, carbon, provided that more than 95% of said fatty acids are C8 and / or C10.
    [0007]
    7. Composition according to any one of the preceding claims, characterized in that the surfactant has an HLB of 1 to 8.
    [0008]
    8. Composition according to any one of the preceding claims, characterized in that the surfactant is chosen from polyglycerol polyricinoleate and PEG-30-dipolyhydroxystearate.
    [0009]
    9. Composition according to any one of the preceding claims, characterized in that the iodinated oil comprises ethyl esters of iodized fatty acids of olive oil or olive oil.
    [0010]
    10. Composition according to any one of claims 2 to 9, characterized in that the size of the droplets of the aqueous phase is from 1 to 200 microns.
    [0011]
    11. Composition according to any one of the preceding claims, characterized in that it has a viscosity at 20 ° C of between 100 and 200 mPa.s and / or a viscosity at 37 ° C of between 40 and 80 mPa.s. .
    [0012]
    12. Composition according to any one of claims 2 to 11 for its use in the treatment of cancer or its metastases.
    [0013]
    13. Process for the preparation of a composition according to any one of claims 2 to 12, comprising the following steps: a) mixing the surfactant as defined in claim 1 in iodized oil, and b) mixing the solution obtained in step a) with an aqueous solution comprising an anticancer agent. Use of a kit comprising: a surfactant of formula (I) as defined in claim 1, an iodinated oil, as combination products for targeting an anticancer agent. 15. Use of a composition according to any one of claims 1, 7 to 9 and 11 as a carrier of an anticancer agent.
    类似技术:
    公开号 | 公开日 | 专利标题
    Zhao et al.2012|Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation
    Kong et al.2007|Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging
    Li et al.2014|Contrast agents for preclinical targeted X-ray imaging
    WO2015118113A1|2015-08-13|Composition for vectorizing an anti-cancer agent
    Shenoy et al.2005|Poly |-modified poly | nanoparticles for targeted delivery of tamoxifen in breast cancer
    Liu et al.2012|Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles
    Chen et al.2013|In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation
    JP2005504070A|2005-02-10|Oil-based paclitaxel composition and formulation for chemical embolization and method for producing the same
    Boissenot et al.2016|Paclitaxel-loaded PEGylated nanocapsules of perfluorooctyl bromide as theranostic agents
    EP3391906A1|2018-10-24|Biodegradable tumor sealant
    CN105853403B|2019-03-29|A kind of paclitaxel palmitate liposome and preparation method thereof
    US20140105829A1|2014-04-17|Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
    Başpınar et al.2019|Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer
    WO2011101859A1|2011-08-25|A novel water soluble curcumin loaded nanoparticulate system for cancer therapy
    Li et al.2018|Dual-targeting liposomes for enhanced anticancer effect in somatostatin receptor II-positive tumor model
    US20210113463A1|2021-04-22|Injectable Water-in-oil Emulsions And Uses Thereof
    Wang et al.2012|Efficacy and biodistribution of tocopheryl polyethylene glycol succinate noncovalent functionalized single walled nanotubes loading doxorubicin in sarcoma bearing mouse model
    Lee et al.2014|Computed tomography-guided screening of surfactant effect on blood circulation time of emulsions: application to the design of an emulsion formulation for paclitaxel
    EP3331494B1|2021-04-21|Composition intended to vectorise an anti-cancer agent
    WO2014165829A2|2014-10-09|Nanoparticle formulations
    CN108853056B|2021-09-14|Folic acid targeted modification carried doxorubicin hydrochloride and gambogic acid nano-structure lipid carrier preparation and preparation method thereof
    Ahmad et al.2012|Applications of nanotechnology in pharmaceutical development
    KR100497258B1|2005-06-28|Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof
    Kwak et al.2020|Sodium Cholate Bile Acid-Stabilized Ferumoxytol-Doxorubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma
    WO2017214468A1|2017-12-14|Nanodroplet compositions for the efficient delivery of anti-cancer agents
    同族专利:
    公开号 | 公开日
    FR3017295B1|2018-01-12|
    MX2016010217A|2016-12-05|
    ZA201605463B|2017-08-30|
    US20160346202A1|2016-12-01|
    RU2016132461A3|2018-09-12|
    EP3102214A1|2016-12-14|
    JP2017505326A|2017-02-16|
    AU2015214230A1|2016-08-25|
    KR20160130992A|2016-11-15|
    CN106255503B|2020-09-11|
    RU2016132461A|2018-02-08|
    HK1225983A1|2017-09-22|
    CN106255503A|2016-12-21|
    WO2015118113A1|2015-08-13|
    CA2938861A1|2015-08-13|
    SG11201606513UA|2016-09-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP2077106A1|2006-10-27|2009-07-08|Controlled Lipo Techs, Inc.|W/o/w emulsion composition|
    WO2012173003A2|2011-06-13|2012-12-20|国立大学法人 千葉大学|Medical tissue-marker and manufacturing method for same|
    EP2719398A2|2011-06-13|2014-04-16|National University Corporation Chiba University|Medical tissue-marker and manufacturing method for same|
    CH672733A5|1987-05-22|1989-12-29|Bracco Ind Chimica Spa|
    JP4113990B2|1996-07-05|2008-07-09|宮崎県|Anticancer agent-containing emulsion preparation and method for producing the same|
    WO2001068720A1|2000-03-13|2001-09-20|Biocure, Inc.|Embolic compositions|
    DE10059430A1|2000-11-30|2002-06-06|Cognis Deutschland Gmbh|Finely divided emulsions|
    CN1555253A|2001-09-13|2004-12-15|韩国科学技术研究院|Oily composition of taxol,preparation for chemical therapeutic embolism and their producing method|
    WO2003022264A1|2001-09-13|2003-03-20|Korea Institute Of Science And Technology|Paclitaxel mixed composition and water-in-oil type emulsion formulation for chemoembolization and preparation method thereof|
    US20080044543A1|2006-08-17|2008-02-21|Mcclements David J|Stabilized emulsions, methods of preparation, and related reduced fat foods|
    WO2008083092A2|2006-12-28|2008-07-10|Dow Corning Corporation|Polynuclear microcapsules|
    RU2480018C2|2007-06-29|2013-04-27|Нестек С.А.|Stable double emulsions|FR3039767B1|2015-08-04|2017-09-08|Guerbet Sa|COMPOSITION FOR VECTORIZING AN ANTICANCER AGENT|
    CN111263632A|2017-07-17|2020-06-09|古斯达威罗斯研究所|Water-in-oil emulsion for injection and use thereof|
    FR3069245B1|2017-07-21|2019-07-26|Guerbet|LIPOPHILIC MACROCYCLIC LIGANDS, THEIR COMPLEXES AND THEIR MEDICAL USES|
    WO2020092815A1|2018-11-01|2020-05-07|Memorial Sloan Kettering Cancer Center|Improved intra-arterial tumor targeting for diagnosis and/or treatment|
    CN111298189A|2018-12-11|2020-06-19|陈传果|Iodized oil suppository easy to inject and preparation method thereof|
    法律状态:
    2016-02-18| PLFP| Fee payment|Year of fee payment: 3 |
    2017-02-23| PLFP| Fee payment|Year of fee payment: 4 |
    2018-02-27| PLFP| Fee payment|Year of fee payment: 5 |
    2020-02-25| PLFP| Fee payment|Year of fee payment: 7 |
    2021-02-23| PLFP| Fee payment|Year of fee payment: 8 |
    2022-02-23| PLFP| Fee payment|Year of fee payment: 9 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1450972|2014-02-07|
    FR1450972A|FR3017295B1|2014-02-07|2014-02-07|COMPOSITION FOR VECTORIZING AN ANTICANCER AGENT|FR1450972A| FR3017295B1|2014-02-07|2014-02-07|COMPOSITION FOR VECTORIZING AN ANTICANCER AGENT|
    CA2938861A| CA2938861A1|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent|
    AU2015214230A| AU2015214230A1|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent|
    JP2016550609A| JP2017505326A|2014-02-07|2015-02-06|Composition for vectorizing anticancer agent|
    SG11201606513UA| SG11201606513UA|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent|
    PCT/EP2015/052527| WO2015118113A1|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent|
    CN201580007327.4A| CN106255503B|2014-02-07|2015-02-06|Compositions for delivery of anticancer agents|
    MX2016010217A| MX2016010217A|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent.|
    KR1020167021534A| KR20160130992A|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent|
    US15/117,109| US20160346202A1|2014-02-07|2015-02-06|Composition for Vectorizing an Anti-Cancer Agent|
    RU2016132461A| RU2016132461A3|2014-02-07|2015-02-06|
    EP15704280.5A| EP3102214A1|2014-02-07|2015-02-06|Composition for vectorizing an anti-cancer agent|
    ZA2016/05463A| ZA201605463B|2014-02-07|2016-08-05|Composition for vectorizing an anti-cancer agent|
    HK16114398A| HK1225983A1|2014-02-07|2016-12-19|Composition for vectorizing an anti-cancer agent|
    [返回顶部]